

Curriculum Vitae

Personal information **Manfred Schuster**

Work experience

1. Employer: AGES GmbH
 - Start date: 102020
 - End date:
 - Position: Head of Department Biologics, Quality, Preclinics and Statistics, Assessor for Biologics
 - Activities:
 - Country: Austria
2. Employer: Origimm GmbH
 - Start date: 012018
 - End date: 092020
 - Position: Chief Development Officer
 - Activities: Development of Vaccines to treat Acne vulgaris and to prevent implant infections
 - Country: Austria
3. Employer: Biotech Consultant
 - Start date: 022016
 - End date: 092020
 - Position: Freelancer
 - Activities: Biotech consulting activities, development and manufacturing of Biologics
 - Country: Austria
4. Employer: University of Vienna
 - Start date: 092013
 - End date:
 - Position: Lecturer
 - Activities: Protein therapeutics and antibiotics
 - Country: Austria
5. Employer: Remute Bio GmbH
 - Start date: 022016
 - End date: 102016
 - Position: CEO
 - Activities: Therapy of osteoporosis
 - Country: Austria
6. Employer: RMB Research GmbH
 - Start date: 092015
 - End date: 072017
 - Position: CEO
 - Activities: Therapy of chronic wounds
 - Country: Austria
7. Employer: Apeiron _Biologics AG
 - Start date: 052009
 - End date: 052015
 - Position: Chief Operating Officer
 - Activities: Therapy of acute lung failure and cancer
 - Country: Austria
8. Employer: Apeiron Biologics GmbH
 - Start date: 092005
 - End date: 042009
 - Position: Vice President R&D
 - Activities: Therapy of acute lung failure and cancer
 - Country: Austria
9. Employer: Igeneon AG
 - Start date: 012000
 - End date: 082005
 - Position: Program manager
 - Activities: Immunotherapy of epithelial cancers
 - Country: Austria

Education and training

1. Subject: AGES, University of Vienna
 - Start date: 092009
 - End date: 062010
 - Qualification: Qualified Person
 - Organisation: Post_graduate University course in Pharmaceutical Quality Management, University of Vienna, Austria
 - Country: Austria
2. Subject: University of Vienna
 - Start date: 091991
 - End date: 031996
 - Qualification: Bachelor of Science
 - Organisation: Chemistry and Biochemistry
 - Country: Austria

3. Subject: Technical University of Vienna
 - Start date: 041996
 - End date: 031997
 - Qualification: Master Degree (Dipl._Ing.)
 - Organisation: Biochemistry, Biotechnology and technical chemistry
 - Country: Austria
4. Subject: University of natural resources, Vienna
 - Start date: 041997
 - End date: 032000
 - Qualification: PhD
 - Organisation: Biotechnology and applied microbiology
 - Country: Austria
5. Subject: University of Vienna
 - Start date: 012011
 - End date: 062013
 - Qualification: Master of Science
 - Organisation: Pharmaceutical quality management
 - Country: Austria

Additional information

Publications

Original Papers Microheterogeneity of recombinant antibodies: analytics and functional impact. Beyer Beate, Schuster Manfred, Jungbauer Alois, Lingg Nico Biotechnol J. 2018 Jan;13(1) Charge heterogeneity: Basic antibody charge variants with increased binding to Fc receptors. Beate Hintersteiner, Nico Lingg, Peiqing Zhang, Susanto Woen, Kong Meng Hoi, Stefan Stranner, Susanne Wiederkum, Oliver Mutschlechner, Manfred Schuster, Hans Loibner, and Alois Jungbauer MABS, 2016, VOL. 0, NO. 0, 1–13 Highly linear pH gradients for analyzing monoclonal antibody charge heterogeneity in the alkaline range: Validation of the method parameters. Lingg N, Berndtsson M, Hintersteiner B, Schuster M, Bardor M, Jungbauer A J Chromatogr A. 2014 Dec 19;1373:124–30. doi: 10.1016/j.chroma.2014.11.021. Epub 2014 Nov 14. Lack of alpha₂ gal glycosylation determinants expressed on antibody ch14.18 produced in Chinese Hamster Ovary (CHO) cells (APN311) Comparison to a ch14.18 variant produced in murine SP2/0 cells Hans Loibner, Manfred Schuster, Oliver Mutschlechner, Franz Groiss, Susanne Wiederkum, Bernhard Peball, Evelyn Janzek, Stefan Stranner, Ruth Ladenstein, Holger Lode Conference paper: International Society of Paediatric Oncology Europe Neuroblastoma 2014, Vienna, Austria; 10/2014 Long term continuous infusion of anti_GD2 antibody CH14.18/CHO in relapsed/refractory neuroblastoma patients Holger Lode, Nikolai Siebert, Silke Kietz, Ina Müller, Manfred Schuster, Evelyn Janzek, Susanne Wiederkum, Oliver Mutschlechner, Hans Loibner J Immunother Cancer 11/2013; 1(Suppl 1):P244. Binding characteristics of the immunocytokine hu14.18_IL2 and induction of human effector functions as anticipated mode of action. Hans Loibner, Manfred Schuster, Evelyn Janzek, Stefan Stranner, Bernhard Peball, Susanne Wiederkum, Oliver Mutschlechner, Nikolai Siebert, Holger Lode Cancer Research 08/2013; 73(8 Supplement):2858–2858 Safety and Therapeutic Efficacy of the Lewis Y Carbohydrate Specific Humanized Antibody MB311 in Patients with Malignant Effusion. T. Bauernhofer, H. Samonigg, P. Regitnik, W. Weitzer, B. Lileg, G. Waxenecker, S. Wiederkum, M. Kainer, M. Schuster3, H. Loibner, M. Fido, R. Kircheis3, A. Nechansky Journal of Cancer Therapy, 2014, 5. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin converting enzyme 2 in healthy human subjects. Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, Penninger J, Krähenbühl S. Clin Pharmacokinet. 2013 Sep;52(9):783–92. doi: 10.1007/s40262-013-0072-7. Adoptive transfer of siRNA Cblb silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model. Hinterleitner R, Gruber T, Pfeifhofer Obermair C, Lutz Nicoladoni C, Tzankov A, Schuster M, Penninger JM, Loibner H, Lametschwandner G, Wolf D, Baier G. PLoS One. 2012;7(9):e44295. doi: 10.1371/journal.pone.0044295. Epub 2012 Sep 4. Recombinant Expression and Characterization of Human and Murine ACE2: Species-Specific Activation of the Alternative Renin-Angiotensin System. Poglitsch M, Domenig O, Schwager C, Stranner S, Peball B, Janzek E, Wagner B, Jungwirth H, Loibner H, Schuster M. Int J Hypertens. 2012;2012:428950. doi: 10.1155/2012/428950. Epub 2012 Feb 28. Murine recombinant angiotensin converting enzyme 2: effect on angiotensin II dependent hypertension and distinctive angiotensin converting enzyme 2 inhibitor characteristics on rodent and human angiotensin converting enzyme 2. Ye M, Wysocki J, Gonzalez Pacheco FR, Salem M, Evora K, Garcia Halpin L, Poglitsch M, Schuster M, Batlle D. Hypertension. 2012 Sep;60(3):730–40. Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y specific monoclonal antibody MB314 Ralf Kircheis, Nicole Halanek, Iris Koller, Wolfgang Jost, Manfred Schuster, Gilbert Gorr, Klaus Hajszan and Andreas Nechansky mAbs 4:4, 532–541 (2012) Recombinant Angiotensin Converting Enzyme 2 Suppresses Pulmonary Vasoconstriction in Acute Hypoxia Axel Kleinsasser, MD; Iris Pircher, MD; Benedict Tremblé, MD; Martin Schwienbacher, MD; Manfred Schuster, PhD; Eveline Janzek, MD; Hans Loibner, PhD; Josef M. Penninger, MD; Alex Loeckinger, MD WILDERNESS & ENVIRONMENTAL MEDICINE, 23, 24–30 (2012) Phase I Dose Escalation Study with the Lewis Y Carbohydrate Specific Humanized Antibody IGN311 Daniel Orazio, Günter Waxenecker, Christoph Aulmann, Bruno Märkl, Theodor Wagner, Geert Mudde, Manfred Schuster, Norbert Eller, Andrea Mayer, Stefan Stranner, Gottfried Himmler, Hans Loibner, Günter Schlimok, Ralf Kircheis, Andreas Nechansky Journal of Cancer Therapy, 2011, 2, 760–771 Angiotensin converting enzyme 2 abrogates bleomycin induced lung injury. Rey-Parra GJ, Vadiel A, Coltan L, Hall A, Eaton F, Schuster M, Loibner H, Penninger JM, Kassiri Z, Oudit GY, Thébaud B. J Mol Med (Berl). 2012 Jun;90(6):637–47 Cytoskeletal defects in Bmpr2 associated pulmonary arterial hypertension. Johnson JA, Hemnes AR, Perrien DS, Schuster M, Robinson LJ, Gladson S, Loibner H, Bai S, Blackwell TR, Tada Y, Harral JW, Talati M, Lane KB, Fagan KA, West J. Am J Physiol Lung Cell Mol Physiol. 2012 Mar 1;302(5):L474–84. doi: 10.1152/ajplung.00202.2011. Epub 2011 Dec 16. Prevention of angiotensin II mediated renal oxidative stress, inflammation, and fibrosis by angiotensin converting enzyme 2 Zhong J, Guo D, Chen CB, Wang W, Schuster M, Loibner H, Penninger JM, Scholey JW, Kassiri Z, Oudit GY. Hypertension. 2011 Feb;57(2):314–22 Angiotensin converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, Loibner H, Wang XH, Penninger JM, Kassiri Z, Oudit GY. Circulation. 2010 Aug 17;122(7):717–28, 18 p following 728 Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin_1 expression Zhong JC, Ye JY, Jin HY, Yu X, Yu HM, Zhu DL, Gao PJ, Huang DY, Schuster M, Loibner H, Guo JM, Yu XY, Xiao BX, Gong ZH, Penninger JM, Oudit GY. Regul Pept. 2011 Jan 17;166(1–3):90–7 Targeting the Degradation of Angiotensin II with Recombinant ACE2: Prevention of Angiotensin II dependent Hypertension and Reduction of Oxidative Stress Jan Wysocki, Minghao Ye, Eva Rodriguez, Francisco R. González Pacheco, Manfred Schuster, Hans Loibner, Josef M. Penninger, and Daniel Batlle Hypertension. 2010 Jan;55(1):90–8 Human recombinant angiotensin converting enzyme 2 reduces the progression of diabetic nephropathy Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, Loibner H, Janzek E, Schuster M, Penninger JM, Herzenberg AM, Kassiri Z, Scholey JW Diabetes. 2009 Nov 23. Angiotensin converting enzyme 2 inhibits liver fibrosis in mice Christoph H. Österreicher, Kojiro Taura, Samuele De Minicis, Ekihiro Seki, Melitta Penz Österreicher, Johannes Kluwe, Gavin Y. Oudit, Josef M. Penninger, Manfred Schuster, Hans Loibner and David A. Brenner Hepatology. 2009 Sep;50(3):929–38 Recombinant angiotensin converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide induced lung injury in piglets. Benedikt Tremblé, Nikolaus Neu, Axel Kleinsasser, Christian Gritsch, Thomas Finsterwalder, Ralf Geiger, Manfred Schuster, Evelyn Janzek, Hans Loibner, Josef Penninger and Alexander Löckinger (submitted 2008) Crit Care Med. 2009 Oct 20. Yeast cell surface display system for determination of humoral response to active immunization with a monoclonal antibody against EpCAM Astrid Dürauer, Eva Berger, Marlene Zandian, Christa Mersich, Manfred Schuster, Hans Loibner, Alois Jungbauer; Journal of Biochemical and Biophysical Methods 2008 70; 1109–1115. Inhibition of Xenograft Tumor Growth and Down-Regulation of ErbB Receptors by an Antibody Directed against Lewis Y Antigen Hesso Farhan, Christian Schuster, Markus Klinger, Eva Weisz, Günter Waxenecker, Manfred Schuster, Veronika Sexl, Geert C. Mudde, Michael Freissmuth, and Ralf Kircheis; The Journal of Pharmacology and experimental Therapeutics 2006; 319:1–8. Compensation of endogenous IgG mediated inhibition of antibody dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies Andreas Nechansky, Manfred Schuster, Wolfgang Jost, Petra Siegl, Susanne Wiederkum, Gilbert Gorr, Ralf Kircheis; Molecular Immunology 2007; 44, 1815–17. Cancer

Immunotherapy, review article Manfred Schuster, Andreas Nechansky, Hans Loibner and Ralf Kircheis; Biotechnology Journal 2006; 1, 138_147. In vivo glyco_engineered antibody with improved lytic potential produced by an innovative nonmammalian expression system Manfred Schuster, Wolfgang Jost, Geert C. Mudde, Susanne Wiederkum, Cornelia Schwager, Evelyn Janzek, Friedrich Altmann, Johannes Stadlmann, Christian Stemmer and Gilbert Gorr, Biotechnology Journal 2007, 2, 700_8. Method for determining humoral response to active immunization with monoclonal antibody against EpCAM using peptide arrays prepared by SPOT technology Dürauer A., Berger E., Schuster M., Wasserbauer E., Mudde G., Himmler G., Jungbauer A., J. Immunol. Methods, 2006, 317, 114_25. Peptide arrays for the determination of humoral responses induced by active immunization with a monoclonal antibody against EpCAM. Dürauer A., Berger E., Schuster M., Wasserbauer E., Himmler G., Loibner H., Mudde G.C., Jungbauer A. J Immunol Methods. 2006 Dec 20;317(1_2):114_25. Epub 2006 Oct 9. Expression of recombinant antibodies using a tri_cistronic expression system. Schuster M, Waxenecker G, Himmler G, Loibner H; Manuscript in preparation Increased effector functions of a therapeutic monoclonal Le_Y specific antibody by glycoform engineering (manuscript in preparation) Improved Effector Functions of a Therapeutic Monoclonal Lewis Y_Specific Antibody by Glycoform Engineering Schuster M, Umana P, Waxenecker G, Wiederkum S, Schwager C, Himmler G, Loibner H, Mudde G.C; Cancer Research 2005; Sep 1;65(17):7934_41.65 (17). Two novel additives for serum and serum_free media increase activity of in_vitro mammalian cells. Karlheinz Landauer, Lucia Strommer, Manuela Kainer, Otto Dobhoff_Dier, Manfred Schuster, Gottfried Himmler, Hans Loibner, Günter Waxenecker, (submitted to Biotechnology Process) Expression and purification of homogenous proteins in Saccharomyces cerevisiae based on ubiquitin_FLAG fusion. Einhauser A, Schuster M, Wasserbauer E, Jungbauer A Protein Expr Purif 2002 Apr 24;3 497_504 Transmembrane_sequence_dependent overexpression and secretion of glycoproteins in Saccharomyces cerevisiae. Schuster M, Wasserbauer E, Aversa G, Jungbauer A Protein Expr Purif 2001 Feb 21;1 1_7 High speed immuno_affinity chromatography on supports with gigapores and porous glass. Schuster M, Wasserbauer E, Neubauer A, Jungbauer A Bioseparation 2000 9:5 259_68 Protein expression in yeast; comparison of two expression strategies regarding protein maturation. Schuster M, Einhauser A, Wasserbauer E, Sussenbacher F, Ortner C, Paumann M, Werner G, Jungbauer A J Biotechnol 2000 Dec 28 84:3 237_48 Short cut of protein purification by integration of cell_disrupture and affinity extraction. Schuster M, Wasserbauer E, Ortner C, Graumann K, Jungbauer A, Hammerschmid F, Werner G Bioseparation 2000 9:2 59_67 Protein expression strategies for identification of novel target proteins. Schuster M, Wasserbauer E, Einhauser A, Ortner C, Jungbauer A, Hammerschmid F, Werner G J Biomol Screen 2000 Apr 5:2 89_97 Solvent production by Clostridium beijerinckii NRRL B592 growing on different potato media. Nimcevic D, Schuster M, Gapes JR Appl Microbiol Biotechnol 1998 Oct 50:4 426_8 Invited talks at international congresses and symposia 2017, Novel Formulation Strategies, SELECT BIO Conference, Hyderabad, India Formulation Strategies for a Biologic to treat Chronic Wounds 2017, Protein Therapeutics, CHI Conference, San Diego, California, USA Innovative and Effective Treatment of Chronic Wounds 2015, Protein Therapeutics, CHI Conference, San Diego, California, USA Late stage development of a chimeric antibody 2014, Biologics R&D Leaders Forum, Brussels, Belgium Developing of human Angiotensin Converting Enzyme 2 up to Phase II and highlighting the therapeutic properties of the enzyme in animal models of cardio_vascular, pulmonary and nephrologic pathologies 2013, VIC Congress 2013 _ Vaccines, Immunotherapies and Cell Therapies, Brussels, Belgium Novel Approaches in Immunotherapy of Neuroblastoma 2013, Biotechnology Conference, Vellore, India Novel Approaches in Immunotherapy of Neuroblastoma 2013, Affinity 2013, Vienna Angiotensin Converting Enzyme 2: Species_specific activation of the alternative Renin_Angiotensin_System 2013, 6th Annual Protein Congress, London Development of an ACE2 based Enzyme Substitution Therapy 2012, Protein & Biopharma Asia Congress, Singapore From the Idea to the Patient and to a Pharma Deal – A Successful Approach in Preclinical and Clinical Development 2012, Third Annual _ Advancing Biologics from the Lab to the Clinic, Munich, Germany Development of an ACE2 based enzyme therapy: From the bench to the patient 2012, Protein Therapeutics, CHI Conference, San Diego, California, USA Next Generation Immuno_Therapy of Cancer: Development of a Disialoganglioside Specific Immuno_Cytokine 2011, Bioprocess INDUSTRY_ACADEMIA Interaction, Vellore, India Keynote Lecture: From the idea to the patient and to a license deal: Development of an ACE2 based enzyme substitution therapy 2011, MMTC, San Francisco, California, USA From the Idea to the Patient and to a Pharma Deal: Discovery: Pre_Clinical and Early Clinical Development of Angiotensin Converting Enzyme 2 2011, Protein Therapeutics, CHI Conference, San Diego, California, USA ACE2: From concept to the patient 2010, Cardio_Vascular Remodelling Conference, Cancun, Mexico ACE2: From the idea to the patient 2009, MMTC, San Francisco, California, USA Preclinical development of an ACE2 enzyme substitution therapy 2009, Protein Therapeutics, CHI Conference, San Diego, California, USA Establishment of an industrial production process for recombinant ACE2 2008, Biotech China, Shanghai, China Treatment of Heart Failure and Fibrosis with the Biologic ACE2 2008, Pepcon, Shenzhen, China ACE2 based Enzyme Substitution Therapy for Treatment of Acute Indications 2008, Protein Therapeutics, CHI Conference, San Diego, California, USA Development of an ACE2 Enzyme Substitution Therapy 2005, Bio_chromatography day, Vienna, Austria Isolation and characterization of iso_forms of recombinant antibodies 2005, Protein Therapeutics, CHI Conference, San Diego, California, USA Development in Cancer Immunotherapy: From a murine to a humanized and finally to a glyco_engineered monoclonal antibody with enhanced effector functions 2004, Cancer Immunotherapeutics, CHI Conference, Boston, Massachusetts, USA Increased effector functions of a monoclonal antibody by glycoform engineering, recent results. 2004, 5th European Symposium on Biochemical Engineering Science, Stuttgart, Germany Increased effector functions of a monoclonal antibody by glycoform engineering 2003, Antibody Production and Downstream Processing, IBC conference, Basel, Switzerland Increased effector functions of a monoclonal antibody by glycoform engineering 2002, Äkta User Seminar, Emmendingen, Germany Automated sequential affinity chromatography 2000, 5th Interlaken Conference on Advances in Production of Recombinant Proteins, Interlaken, Switzerland Comparison of two high throughput expression strategies in S. cerevisiae 1999, 19th International Symposium on the Separation of Proteins, Peptides and Polynucleotides, Delray Beach, Florida, USA High throughput protein expression in Yeast; comparison of two expression strategies 1998, 2nd European Symposium on Biochemical Engineering Science, Porto, Portugal Expression Strategies for Functional Genomics Selected poster presentations at international congresses ASCO 2002 Murine monoclonal antibody 17_1A used as vaccine antigen (IGN101): Direct induction of anti_EpCAM antibodies by vaccination Manfred Schuster, Hans Loibner, Evelyn Janzek, Gottfried Himmler, Jungbauer Alois, Rainer Hahn, Astrid Dürauer, Hellmut Samonigg AACR 2002 Qualitative and Quantitative Dissection of the Immune Response to the Cancer Vaccine Candidates IGN101 and IGN301 Guenter Waxenecker, Gottfried Himmler, Manfred Schuster, Thomas Putz, Erich Wasserbauer, Evelyn Janzek, Renate Ohler, Stefan Stranner, Hans Loibner, Hellmut Samonigg AACR 2002 Treatment of Breast Cancer Patients with the Cancer Vaccine IGN101 that Induces an Immune Response against the Pan_Carcinoma Glycoprotein EpCAM Hellmut Samonigg, Hans Loibner, Manfred Schuster and Gottfried Himmler ASCO 2003 Phase II trial to explore the influence of concomitant chemotherapy on the immunogenicity of the cancer vaccine IGN101 in patients with epithelial cancers H. Samonigg, G. Hofmann, T. Bauernhofer, M. Balic, H. Stoeger1 , G. Himmler, M. Schuster, F. Rosenkaimer, F. Groiss, H. Loibner ASCO 2003 Murine monoclonal antibody 17_1A used as vaccine antigen (IGN101): Direct induction of anti_EpCAM antibodies by vaccination of cancer patients Manfred Schuster, Stefan Stranner, Evelyn Janzek, Hans Loibner, Gottfried Himmler, Hellmut Samonigg Vaccination with alum_adsorbed antibodies against EpCAM directly induces anti_EpCAM antibodies Manfred Schuster, Hans Loibner, Evelyn Janzek, Gottfried Himmler; Marija Balic, Guenter Hofmann, Hellmut Samonigg AACR 2003 Lewis Y / EpCAM co_expression in breast cancer is correlated with poor prognosis Guido Sauter, Manfred Schuster, Gottfried Himmler, Hans Loibner Eurocancer 2003 Expression d'EpCAM dans différents tissus cancéreux et normaux : valeur pronostique dans le cancer du sein Sauter G., Schuster M., Himmler G. and Loibner H. PEACE 2003 Expression of recombinant antibodies using a tri_cistronic expression system M. Schuster, G. Waxenecker, G. Himmler, I. Frohofer, C. Schwager, R. Ohler and H. Loibner, igeneon ISBT 2003 Analysis of the specificity of the humoral oimmune response by cancer vaccine IGN101 Manfred Schuster, Gottfried Himmler, Hans Loibner, Irmgard Frohofer, Cornelia Schwager, Helga Klug, Susanne Wiederkum, Alois Jungbauer, Astrid Dürauer and Rainer Hahn Treatment of Breast Cancer Patients with the Cancer Vaccine IGN101 that Induces an Immune Response against the Pan_Carcinoma Glycoprotein EpCAM Hellmut Samonigg, Hans Loibner, Marija Balic, Guenter Hofmann, Manfred Schuster and Gottfried Himmler AACR 2004, ISBT 2004 Increased effector functions of a monoclonal antibody by glycoform engineering M. Schuster, P. Umana1, P. Brünker1, I. Frohofer, S. Wiederkum, C. Schwager, H. Klug, G.C. Mudde, G. Himmler and H. Loibner Gordon Research Conference, Angiotensin, 2008 Therapeutic effects of an ACE2 enzyme substitution therapy in ARDS M. Schuster, H. Loibner, E. Janzek, B. Tremel and A. Löckinger Recombinant Human ACE2: Treatment of Pulmonary Hypertension in a Piglet Model H. Loibner, M. Schuster, E. Janzek, A. Kleinsasser, B. Tremel and A. Löckinger AACR 2008 Development of recombinant human soluble Angiotensin Converting Enzyme 2 (rhACE2) for cancer therapy Hans Loibner, Evelyn Janzek, Bernhard Peball, Manfred Schuster

Gordon Research Conference, Angiotensin, 2010 rhACE2: Cloning to Clinic M. Schuster, B. Wagner, R. Schaefer, B. Peball, E. Janzek, S. Stranner, A. Löckinger, G. Oudit, C. Oesterreicher, D. Batlle, M. Haschke, S. Kraehenbuehl and H. Loibner ATV conference, 2011 Pharmacology of Recombinant Human Angiotensin Converting Enzyme 2 in Healthy Volunteers Manfred Schuster, Hans Loibner, Marko Poglitsch, Evelyn Janzek, Stefan Stranner, Manuel Haschke, Stephan Kraehenbuehl Immunotherapy of Cancer, Vancouver 2013 Binding characteristics of immunocytokine hu14.18_IL2 (APN301) to its nominal antigen GD2 and to anti_idiotypic antibodies 1A7 and ganglidiomab Manfred Schuster, Susanne Wiederikum, Bernhard Peball, Oliver Mutschlechner, Nikolai Siebert, Sven Brandt, Hans_Peter Müller, Christiane Helm, Holger Lode

Projects

Memberships

Other Relevant Information

Organisational and management skills Experience in executive positions _Executive board member (CEO 2 years, COO 7 years, CDO 3 years) _Head of R&D, Program and Project Manager (6 years) _Core competences: Biologics (CMC), Head of R&D, pharmaceutical development, technical affairs, collaboration management, intellectual property, regulatory affairs and communication with authorities Excellent team_leading skills _Team (up to 15 employees reporting directly) and working group leader (Leadership and communication courses) _Collaboration manager (CMOs, analytical services, clinical and pre_clinical studies, academic collaboration,...) Experienced in supporting biotech partnering processes _Negotiations of in_ and out_licensing deals _Preparation and performance of due_diligences _Expertise in founding and building up biotech companies _Experience in developing pharmaceuticals Technical competence _Qualification for operation, training, development, validation and assessment of various techniques: _Molecular Biology: DNA/RNA techniques, quantitative RT_PCR, si_RNA techniques, generation of expression vectors, protein expression in various hosts _Upstream processing – prokaryotic and eukaryotic expression systems _Chromatography and Downstream processing: Several state of the art analysis and purification techniques (HPLC, IEX, AC, SEC, RPC, HIC,...) _Protein chemistry / Protein analytics / Immunology: Protein isolation, analysis of interaction (S. cerevisiae two hybrid system, FRET), Western Blot, SDS_PAGE, IEF, sequencing, IP, ELISA, enzymology, Luminex, FACS (surface and intra_cellular), SPR (BIAcore) _Cell culture / Fermentation: generation and maintenance of primary cell cultures, transfection, selection and cultivation of standard pro_ and eukaryotic cell lines from lab_scale up to stirred tank and perfusion reactor volumes of 10 l _Cellular assays: ADCC, CDC, WBT, ELISPOT, cell proliferation assays Other competences and qualifications Member of the volunteer fire brigade Schrick (Group Commander), First aid training (AUVA and Red Cross, 2004, 2006, 2011, 2013, 2017 and 2019), poison and hazardous good license, driving licenses for motorcycles, cars, trucks, trailers, traction engines (A, B, C1, C, BE, C1E, CE, F) since 1990, qualified fire safety engineer, lifeguard training, courses in electronics, fulfilled military service, certified advanced open water diver,... Further interests Public understanding of science, electro_techniques, endurance outdoor sports: alpine touring, ski touring, hiking, rock climbing, cycling, diving Inventions and Patent applications 1998 _Integration of cell_disruption and affinity extraction as one step procedure for purification of intracellularly expressed proteins / SW 698, Schuster M, Wasserbauer E 2000 _Production and use of protein_carbohydrate conjugates / ID 2000_001, Eckert H., Loibner H., Schuster M., Himmler, G Waxenecker G., Patent number WO 03/097663, 2002 "Multiepitope Vaccine"AT, PCT 2001 _EpCAM mimotope vaccine / ID 2001_001, Loibner H., Himmler G., Waxenecker G., Schuster M., Putz T, Patent number WO 04/091655, Apr 17, 2003_05_14"Recombinant immunogenic antibody"AT, PCT _IgG2a modified immunoglobulin / ID 2001_002, Loibner H., Himmler G., Waxenecker G., Schuster M., Putz T.Patent number WO 04/091655, Apr 17, 2003"Recombinant immunogenic antibody"AT, PCT 2002 _Tricistronic expression system / ID 2002_002, Loibner H., Himmler G., Waxenecker G., Schuster M. Patent number WO 04/091655, Apr 17, 2003"Recombinant immunogenic antibody"AT _Magnetic beads formulation / ID 2002_003, Himmler G., Loibner H., Schuster M., Wasserbauer E., Eckert H., Doblhoff_Dier O., Kircheis R., Waxenecker G., Patent number WO 02/080966, Mar 23, 2001 _"Autovac II"AT, PCT _Multicompartment Electrophoresis / ID 2002_006, Himmler G., Schuster M., Waxenecker G., Wasserbauer E. _EpCAM fragment / ID 2002_011, Loibner H., Himmler G., Schuster M. _A modular ELISA for simultaneous quantitation / ID 2002_021, Nechansky A., Schuster M., Waxenecker G., Himmler G., Mudde G. 2003 _Multi_epitope vaccine containing a SialylTn carbohydrate conjugate / ID 2003_003, Kircheis R. Schuster M. Himmler G. Loibner H, Patent number WO 03/097663, May 15, 2003"Multiepitope Vaccine"PCT _EpCAM epitopes / ID 2003_005, Loibner H. Himmler G. Jungbauer A. Wasserbauer E. Schuster M. Hahn R. Dürauer A., Patent number WO 04/106917, Jun 02, 2003 "Selection of epitopes for immunotherapy" AT _CIM Discs / ID 2003_006, Loibner H. Waxenecker G. Wasserbauer E. Schuster M. _Low dose vaccine / ID 2003_015, Loibner H. Himmler G. Schuster M., Patent number EP 04450149.2, Jul 2004, "Low dose IGN101", EP _VEGF as target for passive immuno therapy / ID 2003_016, Loibner H. Schuster M. Waxenecker G. 2004 _Antibodies with specific glycosylation and antigenic surface structure / ID 2004_005, Waxenecker G, Himmler G, Loibner H, Landauer K, Schuster M, Kircheis R _Combination therapy passive/active / ID 2004_007, Loibner H, Schuster M _Novel Lewis y antibody / ID 2004_009, Schuster M, Himmler G, Waxenecker G, Mudde G, Loibner H, Loidl M, Redl G, Patent number PCT/EP2004/007787, Jul 14, 2004 "Modified glycosylated antibody" PCT _Increase of targeted cytotoxicity / ID 2004_010, Waxenecker G, Kircheis R, Schuster M, Himmler G, US prov. _Atomadsorptionspectrometry / ID 2004_011, Chabicowsky M, Obwallner A, Schuster M, Szolar O 2005 _Obesity treatment / ID 2005_001, Schuster M, Nechansky A, Wasserbauer E, Kircheis R 2006 _DREAM inhibitors, Schuster M, Loibner H, Stranner S _Immuno_Assay for the quantitative determination of enzymatically active Angiotensin Converting Enzyme 2 (ACE2) in physiological solutions, Schuster M, Loibner H, Janzek E _Glycoengineered antibodies, Schuster M, Gorr G, Nechansky A., Kircheis R _Ex vivo silencing technology, Loibner H, Schuster M, Baier G 2007 _ACE2 therapy of fibrosis, Loibner H, Schuster M, Österreicher C _ACE2 Immuno_modulation, Loibner H, Schuster M. _Glyco_optimized ACE2 with enhanced pharmacological properties, Loibner H, Schuster M, Weik R, Stranner S, Janzek E, Wagner B, Peball B, Kreil B _ACE2 Polypeptide dimer PCT/AT2008/000211, EP 2543724 A3 2008 _ACE2 therapy of cancer, Loibner H, Schuster M, Janzek E, Peball B _ACE2 composition of matter, Schuster M, Loibner H, Weik R, Stranner S, Janzek E, Wagner B, Peball B, Kreil B _Cbl_b siRNA ex vivo therapy: Loibner H, Schuster M, Baier G, Lametschwandtner G 2010 _Cbl_b as biomarker: Loibner H, Schuster M, Baier G, Lametschwandtner G 2011 _Cbl_b inhibition in NK_cells: Loibner H, Schuster M, Lametschwandtner G _RAS Fingerprint: Loibner H, Schuster M, Poglitsch M 2020 _P. acnes vaccine: Selak S., Soellner J., Triska C., Schuster M